Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

A Blueprint for HIV Vaccine Discovery.

Burton DR, Ahmed R, Barouch DH, Butera ST, Crotty S, Godzik A, Kaufmann DE, McElrath MJ, Nussenzweig MC, Pulendran B, Scanlan CN, Schief WR, Silvestri G, Streeck H, Walker BD, Walker LM, Ward AB, Wilson IA, Wyatt R.

Cell Host Microbe. 2012 Oct 18;12(4):396-407. doi: 10.1016/j.chom.2012.09.008. Review.

2.

Progress in HIV-1 vaccine development.

Haynes BF, Moody MA, Alam M, Bonsignori M, Verkoczy L, Ferrari G, Gao F, Tomaras GD, Liao HX, Kelsoe G.

J Allergy Clin Immunol. 2014 Jul;134(1):3-10; quiz 11. doi: 10.1016/j.jaci.2014.04.025. Epub 2014 Jun 26. Review.

3.

Report of the Cent Gardes HIV Vaccine Conference: The B-cell Response to HIV. Part 1: Broadly Neutralizing Antibodies Fondation Mérieux Conference Center, Veyrier du Lac, France, 5-7 November 2012.

Girard MP, Picot V, Longuet C, Nabel GJ.

Vaccine. 2013 Jun 24;31(29):2979-83. doi: 10.1016/j.vaccine.2013.02.068. Epub 2013 Mar 13.

PMID:
23499518
4.

Lessons learned from HIV-1 vaccine trials: new priorities and directions.

McMichael AJ, Haynes BF.

Nat Immunol. 2012 Apr 18;13(5):423-7. doi: 10.1038/ni.2264. Erratum in: Nat Immunol. 2013 Apr;14(4):413.

5.

Broadly Neutralizing Antibodies Against HIV: New Insights to Inform Vaccine Design.

Sadanand S, Suscovich TJ, Alter G.

Annu Rev Med. 2016;67:185-200. doi: 10.1146/annurev-med-091014-090749. Epub 2015 Nov 9. Review.

PMID:
26565674
7.

HIV-1 envelope glycoprotein immunogens to induce broadly neutralizing antibodies.

Sliepen K, Sanders RW.

Expert Rev Vaccines. 2016;15(3):349-65. doi: 10.1586/14760584.2016.1129905. Epub 2016 Jan 8. Review.

PMID:
26654478
8.

Prospects for a globally effective HIV-1 vaccine.

Excler JL, Robb ML, Kim JH.

Vaccine. 2015 Nov 27;33 Suppl 4:D4-12. doi: 10.1016/j.vaccine.2015.03.059. Epub 2015 Jun 20. Review.

PMID:
26100921
9.

New approaches to HIV vaccine development.

Haynes BF.

Curr Opin Immunol. 2015 Aug;35:39-47. doi: 10.1016/j.coi.2015.05.007. Epub 2015 Jun 8. Review.

10.

Broadly Neutralizing Antibody-Guided Carbohydrate-Based HIV Vaccine Design: Challenges and Opportunities.

Liu CC, Zheng XJ, Ye XS.

ChemMedChem. 2016 Feb 17;11(4):357-62. doi: 10.1002/cmdc.201500498. Epub 2016 Jan 13. Review.

PMID:
26762799
11.

Rational HIV immunogen design to target specific germline B cell receptors.

Jardine J, Julien JP, Menis S, Ota T, Kalyuzhniy O, McGuire A, Sok D, Huang PS, MacPherson S, Jones M, Nieusma T, Mathison J, Baker D, Ward AB, Burton DR, Stamatatos L, Nemazee D, Wilson IA, Schief WR.

Science. 2013 May 10;340(6133):711-6. doi: 10.1126/science.1234150. Epub 2013 Mar 28.

12.

Approaches to the induction of HIV broadly neutralizing antibodies.

Moore PL, Williamson C.

Curr Opin HIV AIDS. 2016 Nov;11(6):569-575. Review.

PMID:
27559709
13.

HIV vaccines: progress to date.

Munier CM, Andersen CR, Kelleher AD.

Drugs. 2011 Mar 5;71(4):387-414. doi: 10.2165/11585400-000000000-00000. Review.

PMID:
21395355
14.

Catch Me If You Can--The Race Between HIV and Neutralizing Antibodies.

Geiß Y, Dietrich U.

AIDS Rev. 2015 Apr-Jun;17(2):107-13. Review.

PMID:
26035168
15.

DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers.

Gupta S, Clark ES, Termini JM, Boucher J, Kanagavelu S, LeBranche CC, Abraham S, Montefiori DC, Khan WN, Stone GW.

J Virol. 2015 Apr;89(8):4158-69. doi: 10.1128/JVI.02904-14. Epub 2015 Jan 28.

16.

Current views on the potential for development of a HIV vaccine.

Cohen KW, Frahm N.

Expert Opin Biol Ther. 2017 Mar;17(3):295-303. doi: 10.1080/14712598.2017.1282457. Epub 2017 Jan 23. Review.

PMID:
28095712
17.

Humanized Immunoglobulin Mice: Models for HIV Vaccine Testing and Studying the Broadly Neutralizing Antibody Problem.

Verkoczy L.

Adv Immunol. 2017;134:235-352. doi: 10.1016/bs.ai.2017.01.004. Review.

PMID:
28413022
18.

Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies.

Verkoczy L, Kelsoe G, Moody MA, Haynes BF.

Curr Opin Immunol. 2011 Jun;23(3):383-90. doi: 10.1016/j.coi.2011.04.003. Epub 2011 Apr 27. Review.

19.

Heterologous protection elicited by candidate monomeric recombinant HIV-1 gp120 vaccine in the absence of cross neutralising antibodies in a macaque model.

Page M, Stebbings R, Berry N, Hull R, Ferguson D, Davis L, Duffy L, Elsley W, Hall J, Ham C, Hassall M, Li B, Mee ET, Quartey-Papafio R, Rose NJ, Mathy N, Voss G, Stott EJ, Almond N.

Retrovirology. 2012 Jul 16;9:56. doi: 10.1186/1742-4690-9-56.

20.

Report of the Cent Gardes HIV Vaccine Conference: The B-cell response to HIV. Part 2: Non-neutralizing antibodies: Fondation Mérieux Conference Center, Veyrier du Lac, France 5-7 November 2012.

Girard MP, Picot V, Longuet C, Nabel GJ.

Vaccine. 2013 Jun 24;31(29):2984-7. doi: 10.1016/j.vaccine.2013.02.067. Epub 2013 Apr 18.

PMID:
23602538

Supplemental Content

Support Center